TY - JOUR
T1 - Antimicrobial activities of ceftazidime-avibactam, ceftolozane-tazobactam, and other agents against escherichia coli, klebsiella pneumoniae, and pseudomonas aeruginosa isolated from intensive care units in Taiwan
T2 - Results from the surveillance of multicenter antimicrobial resistance in Taiwan in 2016
AU - Liao, Chun Hsing
AU - Lee, Na Yao
AU - Tang, Hung Jen
AU - Lee, Susan Shin Jung
AU - Lin, Chin Fu
AU - Lu, Po Liang
AU - Wu, Jiunn Jong
AU - Ko, Wen Chien
AU - Lee, Wen Sen
AU - Hsueh, Po Ren
N1 - Publisher Copyright:
© 2019 Liao et al.
PY - 2019
Y1 - 2019
N2 - Objective: The aim of this study was to investigate the in vitro antimicrobial susceptibilities of clinically important Gram-negative bacteria from seven intensive care units in Taiwan in 2016. Materials and methods: In total, 300 non-duplicate isolates of Escherichia coli (n=100), Klebsiella pneumoniae (n=100), and Pseudomonas aeruginosa (n=100) collected from 300 patients were studied. The minimum inhibitory concentrations (MICs) of these isolates to antimicrobial agents were determined using the broth microdilution method. Carbapenemase-encoding genes (bla KPC , bla NDM , bla IMP , bla VIM , and bla OXA-48-like ) were studied for the isolates that were not susceptible to any carbapenems. Sequencing analysis of the mcr genes (mcr-1-5) was conducted for all isolates with colistin MICs ≥4 mg/L. Results: Ertapenem non-susceptibility was detected in 3% (n=3) E. coli and 12% (n=12) K. pneumoniae isolates. The susceptibility rates of imipenem, ceftazidime-avibactam (CAZ-AVB), and ceftolozane-tazobactam (CLZ-TAZ) were 99%, 99%, and 88%, respectively, for E. coli, 91%, 100%, and 80%, respectively, for K. pneumoniae, and 66%, 91%, and 93%, respectively, for P. aeruginosa. Carbapenemase-encoding genes were not detected in E. coli, were detected in four (33.3%) K. pneumoniae isolates that were not susceptible to ertapenem (three harboring blaKPC and one harboring blaOXA-48-like), and were not detected in P. aeruginosa isolates that were not susceptible to imipenem. One K. pneumoniae isolate was resistant to colistin (MIC 4 mg/L) and negative for mcrgenes. Conclusion: CAZ-AVB exhibited excellent activity against carbapenem-resistant Enterobacteriaceae, and CLZ-TAZ exhibited good activity against imipenem-resistant P. aeruginosa.
AB - Objective: The aim of this study was to investigate the in vitro antimicrobial susceptibilities of clinically important Gram-negative bacteria from seven intensive care units in Taiwan in 2016. Materials and methods: In total, 300 non-duplicate isolates of Escherichia coli (n=100), Klebsiella pneumoniae (n=100), and Pseudomonas aeruginosa (n=100) collected from 300 patients were studied. The minimum inhibitory concentrations (MICs) of these isolates to antimicrobial agents were determined using the broth microdilution method. Carbapenemase-encoding genes (bla KPC , bla NDM , bla IMP , bla VIM , and bla OXA-48-like ) were studied for the isolates that were not susceptible to any carbapenems. Sequencing analysis of the mcr genes (mcr-1-5) was conducted for all isolates with colistin MICs ≥4 mg/L. Results: Ertapenem non-susceptibility was detected in 3% (n=3) E. coli and 12% (n=12) K. pneumoniae isolates. The susceptibility rates of imipenem, ceftazidime-avibactam (CAZ-AVB), and ceftolozane-tazobactam (CLZ-TAZ) were 99%, 99%, and 88%, respectively, for E. coli, 91%, 100%, and 80%, respectively, for K. pneumoniae, and 66%, 91%, and 93%, respectively, for P. aeruginosa. Carbapenemase-encoding genes were not detected in E. coli, were detected in four (33.3%) K. pneumoniae isolates that were not susceptible to ertapenem (three harboring blaKPC and one harboring blaOXA-48-like), and were not detected in P. aeruginosa isolates that were not susceptible to imipenem. One K. pneumoniae isolate was resistant to colistin (MIC 4 mg/L) and negative for mcrgenes. Conclusion: CAZ-AVB exhibited excellent activity against carbapenem-resistant Enterobacteriaceae, and CLZ-TAZ exhibited good activity against imipenem-resistant P. aeruginosa.
UR - http://www.scopus.com/inward/record.url?scp=85062954217&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85062954217&partnerID=8YFLogxK
U2 - 10.2147/IDR.S193638
DO - 10.2147/IDR.S193638
M3 - Article
AN - SCOPUS:85062954217
SN - 1178-6973
VL - 12
SP - 545
EP - 552
JO - Infection and Drug Resistance
JF - Infection and Drug Resistance
ER -